1. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. (1st December 2020) Authors: Narayan, Omendra; Bentley, Anthony; Mowbray, Katie; Hermansson, Monika; Pivonka, Dominic; Kemadjou, Eric Ngonga; Belsey, Jonathan Journal: Journal of medical economics Issue: Volume 23:Number 12(2021) Page Start: 1640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗